256 related articles for article (PubMed ID: 32519169)
1. The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
Aleixo GFP; Shachar SS; Deal AM; Nyrop KA; Muss HB; Chen YT; Yu H; Williams GR
Breast Cancer Res Treat; 2020 Aug; 182(3):631-642. PubMed ID: 32519169
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
3. Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population.
Weinberg MS; Shachar SS; Muss HB; Deal AM; Popuri K; Yu H; Nyrop KA; Alston SM; Williams GR
Breast J; 2018 May; 24(3):278-284. PubMed ID: 29139618
[TBL] [Abstract][Full Text] [Related]
4. Association of body composition with function in women with early breast cancer.
Aleixo GFP; Deal AM; Nyrop KA; Muss HB; Damone EM; Williams GR; Yu H; Shachar SS
Breast Cancer Res Treat; 2020 Jun; 181(2):411-421. PubMed ID: 32253683
[TBL] [Abstract][Full Text] [Related]
5. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
6. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.
Caan BJ; Cespedes Feliciano EM; Prado CM; Alexeeff S; Kroenke CH; Bradshaw P; Quesenberry CP; Weltzien EK; Castillo AL; Olobatuyi TA; Chen WY
JAMA Oncol; 2018 Jun; 4(6):798-804. PubMed ID: 29621380
[TBL] [Abstract][Full Text] [Related]
7. Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer.
Aleixo GFP; Yu H; Chen YT; Nyrop KA; Louie RJ; Deal AM; Shachar SS; Muss HB; Williams GR
Breast Cancer Res Treat; 2021 Apr; 186(2):487-495. PubMed ID: 33423178
[TBL] [Abstract][Full Text] [Related]
8. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
Phuong A; Marquardt JP; O'Malley R; Holt SK; Laidlaw G; Eagle Z; Ngo S; Orcutt D; Schade GR; Lin DW; Schweizer MT; Yezefski T; Yu EY; Montgomery B; Grivas P; Fintelmann FJ; Psutka SP
Urol Oncol; 2022 Oct; 40(10):456.e19-456.e30. PubMed ID: 36028450
[TBL] [Abstract][Full Text] [Related]
9. Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.
Sheean P; Gomez-Perez S; Joyce C; O'Connor P; Bojko M; Smith A; Vasilopoulos V; Rao R; Sclamberg J; Robinson P
Breast Cancer Res Treat; 2021 Nov; 190(1):121-132. PubMed ID: 34389926
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy.
Ueno A; Yamaguchi K; Sudo M; Imai S
Support Care Cancer; 2020 Sep; 28(9):4249-4254. PubMed ID: 31900607
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach.
Martin L; Hopkins J; Malietzis G; Jenkins JT; Sawyer MB; Brisebois R; MacLean A; Nelson G; Gramlich L; Baracos VE
Ann Surg Oncol; 2018 Sep; 25(9):2669-2680. PubMed ID: 30006691
[TBL] [Abstract][Full Text] [Related]
12. Body composition measures as a determinant of Alpelisib related toxicity.
Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
[TBL] [Abstract][Full Text] [Related]
13. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Xu MC; Huelster HL; Hatcher JB; Avulova S; Stocks BT; Glaser ZA; Moses KA; Silver HJ
J Urol; 2021 Mar; 205(3):800-805. PubMed ID: 33080148
[TBL] [Abstract][Full Text] [Related]
14. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
16. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
[TBL] [Abstract][Full Text] [Related]
17. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.
Dolan RD; Almasaudi AS; Dieu LB; Horgan PG; McSorley ST; McMillan DC
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):111-122. PubMed ID: 30460764
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease.
Grillot J; D'Engremont C; Parmentier AL; Lakkis Z; Piton G; Cazaux D; Gay C; De Billy M; Koch S; Borot S; Vuitton L
Clin Nutr; 2020 Oct; 39(10):3024-3030. PubMed ID: 31980183
[TBL] [Abstract][Full Text] [Related]
19. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
20. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
